Dr Bruno Osterwalder
Dr Bruno Osterwalder is a board certified hematologist and oncologist with a background of 15 years of academic & clinical practice in internal medicine, hematology and oncology (Swiss board certifications). This was followed by 18 years of experience in functions with increasing scientific and managerial responsibilities in global drug development and strategic portfolio management at F. Hoffmann-Roche Basel in the areas of hematology, oncology and renal and cancer anemia. This was followed by over 6 years in Merck Serono Darmstadt in the areas of global hemato-oncology and immuno-oncology drug development with a focus on early POC stages, translational medicine questions, Chinese and Japanese developments and strategic portfolio advice to top management. This resulted in a deep understanding of all modern drug development stages from research transitioning into humans up to global registrations and life cycle management with NCE’s and NBE’s including immunotherapeutics and vaccines.
As member of BD teams, steering committees and advisory boards Dr. Osterwalder is used to assess and analyze research and clinical programs and company portfolios, allowing him to build an extensive network with many biotech and pharma companies around the world. Interactions with regulatory authorities included the US, EU, Japan, Australia and Canada and had led to successful worldwide registrations for several hemato-oncology compounds and an anemia treatment compound. Presentations to various scientific, regulatory and public audiences were made at international conferences.
Since May 2015 Dr. Osterwalder is acting as a consultant and board director to mostly smaller pharmaceutical companies (biotech’s), located in Europe, the USA and Asia. The focus is on strategic portfolio planning and strategic drug development aspects in oncology, hematology and immune-oncology and early clinical trial designs. Specific expertise includes the transition from preclinical to early clinical development, the combined development of companion diagnostics with therapeutic drugs in the context of targeted therapies as well as early development in the field of immuno-oncology. Dr. Osterwalder is a member of professional societies such as ASCO, AACR, ASH, ECCO and ESMO.
Cutting-Edge Cancer Immunotherapy
60F avenue Rockefeller
69008 Lyon, FRANCE